Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Canadian Imperial Bank of Commerce Offers $6.44M Basket Notes (NYSE: CM)

Canadian Imperial Bank of (NYSE: CM) Commerce is offering $6,439,000 ($6.44 million) of senior global medium-term digital basket-linked notes. Payments depend on the performance of a weighted basket of equity indexes through the determination date, giving investors an outcome tied to index performance rather …

Vinay Lochav | 04 September 2026

Medicus Pharma (NASDAQ: MDCX) Falls 34% Despite Pfizer Licensing Deal

Medicus Pharma Ltd. (NASDAQ: MDCX) shares closed down 34% at $0.17 following a worldwide licensing agreement with Pfizer for the early-stage CD228V ADC asset PF-08046031.

Nitish Kishor | 04 September 2026

Hutchmed (NASDAQ: HCM) Rises 17% on GSK Licensing Deal for HMPL-A830

Hutchmed (China) Limited (NASDAQ: HCM) shares closed up 17% at $14.11 after entering an exclusive ex-China development and commercialization license with GSK for HMPL-A830, receiving $110 million upfront and up to $1.3 billion in total milestones plus royalties.

Nitish Kishor | 04 September 2026

Aptevo Therapeutics (NASDAQ: APVO) Falls 34% Despite Strong Interim AML Data

Aptevo Therapeutics, Inc. (NASDAQ: APVO) shares closed down 34% at $1.71 despite reporting interim RAINIER data in frontline TP53-mutated AML showing 93% clinical benefit and 79% CR/CRi among 14 evaluable patients treated with mipletamig plus venetoclax and azacitidine.

Nitish Kishor | 04 September 2026

BioRestorative Therapies (NASDAQ: BRTX) Falls 29% Ahead of 1-for-20 Reverse Stock Split

BioRestorative Therapies, Inc. (NASDAQ: BRTX) shares closed down 29% at $0.14 as the company is set to execute a 1-for-20 reverse stock split on September 7, 2026.

Nitish Kishor | 04 September 2026

bioAffinity Technologies (NASDAQ: BIAF) Rises 31% on CyPath Lung Monitoring Advancement

bioAffinity Technologies, Inc. (NASDAQ: BIAF) shares closed up 31% at $12.78 as the company advances its CyPath Lung platform for post-therapeutic lung cancer monitoring.

Nitish Kishor | 04 September 2026

Biotech News Roundup: Key Developments From September 3-4, 2026

Biotech news over September 3 and 4, 2026 spanned a wide range of developments, from a new FDA approval and a major licensing deal to a clinical trial miss and several financing and corporate updates across more than a dozen companies.

Nitish Kishor | 04 September 2026

Ultragenyx (NASDAQ: RARE) Falls 44% as Angelman Syndrome Trial Misses Endpoint

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares closed down 44% at $14.85 after its trial for Angelman syndrome failed to meet its primary endpoint, marking a clinical setback for the program.

Nitish Kishor | 04 September 2026

4D Molecular Therapeutics (NASDAQ: FDMT) Chief Legal Officer Executes Routine Share Sale

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) Chief Legal Officer Scott Bizily executed a sequence of option exercises and subsequent sales involving 584 shares at prices between $6.49 and $14.

Nitish Kishor | 04 September 2026

Senti Biosciences (NASDAQ: SNTI) Raises $2 Million via Convertible Notes Ahead of Merger

Senti Biosciences, Inc. (NASDAQ: SNTI) raised $2 million via senior secured convertible notes issued to NSG BioInnovation Fund and established a $2.5 million equity agreement with a Celadon affiliate contingent on its pending merger.

Nitish Kishor | 04 September 2026
Support

Hi! How can we help you today?

Loading…